Evidence map›Paper›PMID 38558141›Full record

ArticleJAMA network open2024

Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration.

Adam M Staffaroni, Annie L Clark, Jack C Taylor, Hilary W Heuer, Mark Sanderson-Cimino, Amy B Wise, Sreya Dhanam, Yann Cobigo, Amy Wolf, Masood Manoochehri and 41 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Digital seed amplification assay for TDP-43 aggregate quantification in CSF.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Digital seed amplification assay for TDP-43 aggregate quantification in CSF.medRxiv : the preprint server for health sciences · 2025
    Article
  14. Review
  15. Developing digital health technologies for frontotemporal degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors at 20 institutions in 2 countries.

Adam M StaffaroniDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Annie L ClarkDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Jack C TaylorDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Hilary W HeuerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Mark Sanderson-CiminoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Amy B WiseDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Sreya DhanamDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Yann CobigoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Amy WolfDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Masood ManoochehriDepartment of Neurology, Columbia University, New York, New York.
Leah ForsbergDepartment of Neurology, Mayo Clinic, Rochester, Minnesota.
Carly MesterDepartment of Quantitative Health Sciences, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Katherine P RankinDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Brian S ApplebyDepartment of Neurology, Case Western Reserve University, Cleveland, Ohio.
Ece BayramDepartment of Neurosciences, University of California, San Diego, La Jolla.
Andrea BozokiDepartment of Radiology, University of North Carolina, Chapel Hill.
David ClarkDepartment of Neurology, Indiana University, Indianapolis.
R Ryan DarbyDepartment of Neurology, Vanderbilt University, Nashville, Tennessee.
Kimiko Domoto-ReillyDepartment of Neurology, University of Washington, Seattle.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Douglas GalaskoDepartment of Neurosciences, University of California, San Diego, La Jolla.
Daniel GeschwindDepartment of Neurology, Institute for Precision Health, University of California, Los Angeles.
Nupur GhoshalDepartment of Neurology, Knight Alzheimer Disease Research Center, Washington University, Saint Louis, Missouri.
Neill Graff-RadfordDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida.
Murray GrossmanDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Ging-Yuek HsiungDivision of Neurology, University of British Columbia, Musqueam, Squamish & Tsleil-Waututh Traditional Territory, Vancouver, Canada.
Edward D HueyDepartment of Neurology, Columbia University, New York, New York.
David T JonesDepartment of Quantitative Health Sciences, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Maria I LapidDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.
Irene LitvanDepartment of Neurosciences, University of California, San Diego, La Jolla.
Joseph C MasdeuDepartment of Neurology, Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston Methodist, Houston, Texas.
Lauren MassimoDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Mario F MendezDepartment of Neurology, UCLA (University of California, Los Angeles).
Toji MiyagawaDepartment of Neurology, Mayo Clinic, Rochester, Minnesota.
Belen PascualDepartment of Neurology, Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston Methodist, Houston, Texas.
Peter PressmanDepartment of Neurology, University of Colorado, Aurora.
Vijay K RamananDepartment of Neurology, Mayo Clinic, Rochester, Minnesota.
Eliana Marisa RamosDepartment of Neurology, David Geffen School of Medicine, UCLA.
Katya RascovskyDepartment of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Erik D RobersonDepartment of Neurology, University of Alabama, Birmingham.
M Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
Bonnie WongDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston.
Bruce L MillerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Walter KremersDepartment of Quantitative Health Sciences, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Jason HassenstabDepartment of Neurology, Knight Alzheimer Disease Research Center, Washington University, Saint Louis, Missouri.
Joel H KramerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, Minnesota.
Howard J RosenDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
Adam L BoxerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco.
ALLFTD Consortium
University of California, San Francisco · USMayo Clinic · USMayo Clinic in Florida · USUniversity of California San Diego · USUniversity of Pennsylvania · USColumbia University · USUniversity of California, Los Angeles · USCase Western Reserve University · USUniversity of Alabama at Birmingham · USUniversity of British Columbia · CAUniversity of Colorado Anschutz Medical Campus · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CAUniversity of Washington · USVanderbilt University · USWeill Cornell Medicine · USCornell University · USHarvard University · USIndiana University – Purdue University Indianapolis · USJacksonville College · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
The Frontotemporal Lobar Degeneration Neuroimaging InitiativeR01AG032306 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2009 to 2013
$10.0M
Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
NIA NIH HHS K23 AG059888NIA NIH HHS K23 AG059891NIA NIH HHS K23 AG061253NIA NIH HHS K23 AG073514NIA NIH HHS K24 AG045333NIA NIH HHS L30 AG069301NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG032306NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG058233NIA NIH HHS R01 AG062268NIA NIH HHS R01 AG077557NIA NIH HHS RF1 AG032289NIA NIH HHS RF1 AG077557NIA NIH HHS T32 AG049663NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG045390NIA NIH HHS U01 AG079850NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NIMH NIH HHS R01 MH120794NINDS NIH HHS R01 NS050915NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

Importance: Frontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, and standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers to trial recruitment and success, but no such tools are validated for FTLD. Objective: To evaluate the reliability and validity of smartphone-based cognitive measures for remote FTLD evaluations. Design, Setting, and Participants: In this cohort study conducted from January 10, 2019, to July 31, 2023, controls and participants with FTLD performed smartphone application (app)-based executive functioning tasks and an associative memory task 3 times over 2 weeks. Observational research participants were enrolled through 18 centers of a North American FTLD research consortium (ALLFTD) and were asked to complete the tests remotely using their own smartphones. Of 1163 eligible individuals (enrolled in parent studies), 360 were enrolled in the present study; 364 refused and 439 were excluded. Participants were divided into discovery (n = 258) and validation (n = 102) cohorts. Among 329 participants with data available on disease stage, 195 were asymptomatic or had preclinical FTLD (59.3%), 66 had prodromal FTLD (20.1%), and 68 had symptomatic FTLD (20.7%) with a range of clinical syndromes. Exposure: Participants completed standard in-clinic measures and remotely administered ALLFTD mobile app (app) smartphone tests. Main Outcomes and Measures: Internal consistency, test-retest reliability, association of smartphone tests with criterion standard clinical measures, and diagnostic accuracy. Results: In the 360 participants (mean [SD] age, 54.0 [15.4] years; 209 [58.1%] women), smartphone tests showed moderate-to-excellent reliability (intraclass correlation coefficients, 0.77-0.95). Validity was supported by association of smartphones tests with disease severity (r range, 0.38-0.59), criterion-standard neuropsychological tests (r range, 0.40-0.66), and brain volume (standardized β range, 0.34-0.50). Smartphone tests accurately differentiated individuals with dementia from controls (area under the curve [AUC], 0.93 [95% CI, 0.90-0.96]) and were more sensitive to early symptoms (AUC, 0.82 [95% CI, 0.76-0.88]) than the Montreal Cognitive Assessment (AUC, 0.68 [95% CI, 0.59-0.78]) (z of comparison, -2.49 [95% CI, -0.19 to -0.02]; P = .01). Reliability and validity findings were highly similar in the discovery and validation cohorts. Preclinical participants who carried pathogenic variants performed significantly worse than noncarrier family controls on 3 app tasks (eg, 2-back β = -0.49 [95% CI, -0.72 to -0.25]; P < .001) but not a composite of traditional neuropsychological measures (β = -0.14 [95% CI, -0.42 to 0.14]; P = .32). Conclusions and Relevance: The findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. Smartphone assessments should be considered as a complementary approach to traditional in-person trial designs. Future research should validate these results in diverse populations and evaluate the utility of these tests for longitudinal monitoring.

Indexed as

Frontotemporal DementiaFrontotemporal Lobar DegenerationAdultAgedClinical Trials as TopicCohort StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsReproducibility of ResultsSmartphone

Identifiers

PMID38558141
PMCPMC10985553
OpenAlexW4393375382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.